The global drug infusion pumps market size was valued at USD 10.56 billion in 2022 and is likely to reach USD 18.7 billion by 2031, expanding at a CAGR of 7.6% during 2023 – 2031. The rising prevalence of non-communicable diseases is expected to fuel the market.
An implantable drug infusion pump is used to administer drugs to the targeted area for the treatment of severe intractable pain in patients with non-communicable diseases, such as cancer. Thus, the demand for medical drug delivery pumps to treat an increasing number of people suffering from non-communicable diseases is contributing to the market expansion.
Drug Infusion pumps infuse large or small amounts of medication, such as infusion antibiotics, insulin, hormones, pain relievers, and others. Gravity infusion devices are the most common type of drug infusion pump used to deliver drugs. Moreover, these pumps are majorly utilized to deliver chemotherapy drugs into the patient’s body which kill fast-growing cancer cells.
- For instance, according to the Centers for Diseases Control and Prevention, approximately 1 million individuals in the US undergo chemotherapy as a part of their cancer treatment annually.
The COVID-19 pandemic moderately impacted the market. The pandemic had led to an increase in the number of patients requiring hospitalization and intensive care, particularly for respiratory support. Infusion pumps are crucial in delivering medications, fluids, and nutrition to these patients.
With the rising patient load, healthcare facilities have experienced a higher demand for infusion pumps to ensure accurate and controlled drug administration. On the other hand, the pandemic has disrupted the production and distribution of medical devices. Thus, disruptions in the global supply chain and strain on manufacturing capabilities have affected the availability of these devices.
Drug Infusion Pumps Market Dynamics
Major Drivers
Increasing prevalence of chronic disorders is expected to drive the market during the projected period. Drug infusion pumps play a crucial role in delivering medications and drug fluids directly into the patient's body in a controlled and precise manner. Furthermore, the growing need for chronic disease management among the geriatric population is propelling the demand for drug infusion pumps, as chronic diseases often require these pumps to control severe pain.
-
As per the report published by Who on September 16, 2022, chronic diseases kill about 41 million people each year, which is equivalent to 74% of all global deaths. Cardiovascular diseases kill nearly 17.9 million people, followed by cancer (9.3 million) and diabetes including kidney diseases (2 million) deaths.
Existing Restraints
The stringent government regulations associated with manufacturing infusion pumps, to meet specific quality and safety standards to protect patient well-being are expected to hinder the market. Compliance with regulatory requirements involves extensive testing, documentation, and rigorous approval processes which may force manufacturers to delay the product launching. Furthermore, these regulations may increase manufacturing costs and restrain the market to a certain limit.
Emerging Opportunities
Ongoing technological advancement is expected to create favorable opportunities for market players competing in the market. Advancements such as miniaturization, wireless connectivity, and smart features enable the development of more user-friendly, efficient, and intelligent drug infusion pumps. Moreover, these technological improvements enhance the accuracy of drug delivery to assure patient safety.
Scope of the Drug Infusion Pumps Market Report
The report on the market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Drug Infusion Pumps Market- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Type (Volumetric Pumps, Syringe Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Implantable Pumps, PCA Pumps, ambulatory pumps, and Others), Application (Oncology, Diabetes, Gastroenterology, Pain Management, Pediatrics, Hematology, and Others), and End-User (Hospitals, Clinics, Home Care Settings, and Others)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
B. Braun SE; Baxter; Becton, Dickinson and Company; F. Hoffmann-La Roche Ltd.; Fresenius SE & Co. KGaA; ICU Medical, Inc.; Isulet Corporation; Medtronic; Shenzhen Mindray Bio-Medical Electronics Co., Ltd; Tandem Diabetes Care, Inc.; MicroPort Medical (Group) Co.,Ltd.; and Terumo Corporation
|
Market Segment Insights
Type Segment Analysis
Based on type, the drug infusion pumps market is divided into volumetric pumps, syringe pumps, enteral pumps, insulin pumps, elastomeric pumps, implantable pumps, PCA pumps, ambulatory pumps, and others. The insulin pumps segment is estimated to hold a major market share in the coming years, due to the increasing incidents of both type 1 and type 2 diabetes. Insulin pumps are specialized drug infusion pumps designed specifically for individuals with diabetes who require insulin therapy.
The volumetric pumps segment is anticipated to register lucrative growth, owing to its extensive use in intravenous (IV) therapy, where medications or fluids need to be delivered directly into a patient's vein. This pump has programmable settings, alarms, and safety mechanisms to ensure precise medication delivery, which further contributes to the segment growth.
Application Segment Analysis
On the basis of application, the market is classified as oncology, diabetes, gastroenterology, pain management, pediatrics, hematology, and others. The diabetes segment is anticipated to register a robust growth rate during the projected period, as infusion pumps provide a reliable solution for diabetes patients who need insulin. This pump gives insulin in a controlled and efficient manner to ensure patients safety.
The oncology segment is expected to grow at a significant CAGR during the assessment period, owing to the increasing occurrences of various cancers. Drug infusion pumps are important in chemotherapy to deliver anti-cancer drugs precisely. This further optimizes treatment outcomes and improves patient well-being. The segment growth is further attributed to the rising incidence of cancer is likely to fuel the segment.
End-user Segment Analysis
In terms of end-user, the drug infusion pumps market is fragmented into hospitals, clinics, home care settings, and others. The hospitals segment is expected to hold a key share of the market during the projected period, due to the extensive usage and demand for drug infusion pumps. Hospitals cater to a wide range of medical treatments and procedures including cancer treatments and other critical treatments, which often requires drug infusion pumps.
The home care setting segment is anticipated to expand at a considerable CAGR in the coming years, owing to the increasing need for care in the comfort of patients’ home, especially among elderly population. Home healthcare enables patients to receive their treatments without having to stay in the hospital for an extended period. Furthermore, geriatric people with chronic diseases often require regular monitoring, which in turn boosts the demand for infusion pumps in home care settings.
Regional Outlook
In terms of region, the global drug infusion pumps market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the high implementation rate of drug infusion pumps and the increasing prevalence of diabetes. Diabetic condition often requires long-term therapy of drugs, which creates substantial demand for drug infusion pumps in the region.
The market in Asia Pacific is anticipated to grow at a rapid pace in the coming years, owing to the rising burden of chronic conditions such as diabetes, cardiovascular diseases, and cancer. This in turn boosts the demand for drug infusion pumps in the region.
- As per a report published by the Ministry of Science and Technology of the Government of India on Feb 10, 2022, Non-communicable diseases are rising in India and are the primary reason for 53% of all deaths. Furthermore, India has the high population of diabetes in the world, accounting for 77 million patients and is expected to reach 134 million in 2045.
Segments
The global drug infusion pumps market has been segmented on the basis of
Type
- Volumetric Pumps
- Syringe Pumps
- Ambulatory Pumps
- Others
Application
- Oncology
- Diabetes
- Gastroenterology
- Pain Management
- Pediatrics
- Hematology
- Others
End-User
- Hospitals
- Clinics
- Home Care Settings
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- B. Braun SE
- Baxter
- Becton, Dickinson and Company
- F. Hoffmann-La Roche Ltd.
- Fresenius SE & Co. KGaA
- ICU Medical, Inc.
- Isulet Corporation
- Medtronic
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd
- Tandem Diabetes Care, Inc.
- Terumo Corporation
Competitive Landscape
Key players competing in the global drug infusion pumps market are B. Braun SE; Baxter; Becton, Dickinson and Company; F. Hoffmann-La Roche Ltd.; Fresenius SE & Co. KGaA; ICU Medical, Inc.; Isulet Corporation; Medtronic; Shenzhen Mindray Bio-Medical Electronics Co., Ltd; Tandem Diabetes Care, Inc.; MicroPort Medical (Group) Co.,Ltd.; and Terumo Corporation.
Some of these companies are adopting various strategies such as partnerships, mergers, reduction in production costs, launching new products, and implementing advanced technologies in existing products to cater to customers worldwide. For instance,
- On March 22, 2022, MicroPort Medical, an international medical device supplier, received approval from the Chinese government for its newly developed AutoEx Chemotherapy Infusion Pump (AutoEx). This new pump is equipped with a dual CPU control system and power supply for better precision and control over infusion to improve patient safety.